Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Receivables (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Receivables for 13 consecutive years, with $622000.0 as the latest value for Q4 2025.

  • Quarterly Receivables fell 46.88% to $622000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $622000.0 through Dec 2025, down 46.88% year-over-year, with the annual reading at $622000.0 for FY2025, 46.88% down from the prior year.
  • Receivables for Q4 2025 was $622000.0 at Plus Therapeutics, down from $2.0 million in the prior quarter.
  • The five-year high for Receivables was $2.0 million in Q2 2025, with the low at $622000.0 in Q4 2025.